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Graphical representation of changes in urinary and plasma volume and osmolality. As more glucose is excreted as a result of sodium-glucose
co-transporter 2 (SGLT2) inhibition, more water is drawn to the urine keeping osmolality constant. As a result of increased electrolyte free water
excretion, plasma osmolality is moderately increased and total volume of plasma and interstitial fluid is decreased.
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Aims Sodium–glucose co-transporter 2 (SGLT2) inhibitors improve clinical outcome in patients with heart failure (HF), but
the mechanisms behind their beneficial effects are not yet fully understood. We examined the effects of empagliflozin
on renal sodium and glucose handling in patients with acute HF.
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Methods
and results
This study was a pre-defined sub-study of a double-blind, randomized, placebo-controlled, multicentre study
(EMPA-RESPONSE-AHF). Patients were allocated within 24 h of an acute HF admission to either empagliflozin
10 mg/day (n = 40) or placebo (n = 39) for 30 days. Markers of glucose and sodium handling were measured daily
during the first 96 h and at day 30. Patients were 76 (range 38–89) years old and 33% had diabetes. The use of loop
diuretics during the first 96 h was similar in both groups. Empagliflozin increased fractional glucose excretion with a
peak after 24 h (21.8% vs. 0.1%; P< 0.001), without affecting plasma glucose concentration, while fractional sodium
and chloride excretion and urinary osmolality remained unchanged (P >0.3 for all). However, empagliflozin increased
plasma osmolality (delta osmolality at 72 h: 5± 8 vs. 2± 5 mOsm/kg; P = 0.049). Finally, there was an early decline in
estimated glomerular filtration rate with empagliflozin vs. placebo (−10± 12 vs. −2±12 mL/min/1.73 m2; P = 0.009),
which recovered within 30 days.
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Conclusion In patients with acute HF, empagliflozin increased fractional glucose excretion and plasma osmolality, without affecting
fractional sodium excretion or urine osmolality and caused a temporary decline in estimated glomerular filtration
rate. This suggests that empagliflozin stimulates osmotic diuresis through increased glycosuria rather than natriuresis
in patients with acute HF.
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Keywords Acute heart failure • Sodium–glucose co-transporter 2 inhibitors • Empagliflozin • Diuresis •
Kidney
Introduction
In patients with diabetes and/or chronic kidney disease,
sodium–glucose co-transporter 2 (SGLT2) inhibitors consis-
tently showed beneficial effects on cardiovascular outcomes and
particularly on heart failure (HF) hospitalizations.1–4 Recently, one
larger randomized clinical trial demonstrated that dapagliflozin
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.. reduced cardiovascular death and HF hospitalizations in patients
with established chronic HF with reduced ejection fraction (HFrEF)
with and without diabetes.5 A post-hoc analysis showed that
treatment with dapagliflozin was safe and effective regardless of
diuretic use or dose.6 The beneficial effects of SGLT2 inhibitors
on HF outcomes have been attributed to cardiometabolic and
renal protective qualities, as well as to its diuretic properties.
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Table 1 Baseline characteristics
Empagliflozin (n = 40) Placebo (n = 39) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age (years) 79 (73–83) 73 (61–83) 0.141
Female sex 16 (40) 10 (26) 0.263
Systolic blood pressure (mmHg) 128± 22 121± 25 0.253
eGFR (mL/min/1.73 m2) 53±18 54±16 0.824
Plasma osmolality (mOsm/kg) 305 (302–309) 305 (302–312) 0.691
Urine osmolality (mOsm/kg) 330 (322–379) 341 (324–384) 0.530
Plasma levels of:
Creatinine (mg/dL) 1.3± 0.4 1.3± 0.4 0.723
Urea (mmol/L) 11.0 (7.5–12.8) 9.0 (7.3–13.1) 0.916
Sodium (mmol/L) 140 (137–142) 140 (138–142) 0.806
Potassium (mmol/L) 3.9 (3.5–4.2) 3.9 (3.5–4.4) 0.406
Glucose (mmol/L) 7.9 (6.2–9.6) 7.7 (6.3–8.8) 0.323
Renin (pg/mL) 12.4 (4.8–63.4) 80.1 (14.0–179.3) 0.011
Aldosterone (pg/mL) 182.3 (130.5–292.0) 192.7 (114.6–344.3) 0.653
Urinary levels of:
Creatinine (mmol/L) 3.5 (1.9–5.5) 3.4 (2.0–5.1) 0.944
Urea (mmol/L) 111 (60–142) 98 (78–140) 0.976
Sodium (mmol/L) 100 (68–110) 92 (69–112) 0.734
Potassium (mmol/L) 27 (21–33) 29 (20–41) 0.399
Glucose (mmol/L) 0.2 (0.1–0.3) 0.1 (0.1–0.2) 0.264
Fractional excretion of (%):
Sodium 2.1 (0.9–4.1) 2.2 (0.9–4.4) 0.964
Glucose 0.1 (0.1–0.1) 0.1 (0.0–0.1) 0.890
Categorical variables are depicted as n (%), normally distributed variables are depicted as mean± standard deviation, non-parametric variables are depicted as median
(interquartile range).
eGFR, estimated glomerular filtration rate.
These were even described in chronic ‘stable’ euvolaemic HF.6–8 In
acute HF, we recently showed that early addition of empagliflozin
to standard diuretic treatment increased cumulative diuresis after
4 days with a possible reduction in HF-related events.9 However,
the mechanisms behind increased diuresis of SGLT2 inhibitors in
acute HF are unknown.10,11 In the present mechanistic study, we
investigated the effect of SGLT2 inhibition on renal function, and
urinary sodium, chloride and glucose excretion in acute HF patients
randomized to either empagliflozin or placebo.
Methods
Patients
The present study is a pre-defined analysis of the EMPA-
RESPONSE-AHF trial of which the rationale and main results
have been published recently.9 In short, EMPA-RESPONSE-AHF was a
double-blind, placebo-controlled multicentre pilot study enrolling 79
patients in five centres in the Netherlands, on the safety and efficacy
of empagliflozin in patients with acute HF. Within 24 h of hospital
admission, patients were randomized 1:1 to either empagliflozin
10 mg (for 30 days) (n = 40) or matching placebo (n = 39). The trial
was approved by the ethics committee at each study centre and the
study was conducted in accordance with the Declaration of Helsinki
and the International Conference on Harmonization Guidelines for
Good Clinical Practice. All patients participating in the trial provided







































Spot urine and plasma samples were collected at baseline, daily dur-
ing the first 96 h of hospitalization and after 30 days. Serum sodium,
glucose, and creatinine and spot urinary creatinine and sodium were
measured as part of safety monitoring and were analysed according
to procedures of the local laboratories of each participating hospital.
Urinary glucose, chloride and osmolality were measured at a central
laboratory in the University Medical Center Groningen (UMCG) in
frozen samples. All samples were stored at –80∘C within 2 h of col-
lection and thawed before analysis. Urinary glucose was measured only
after database lock to ensure maintenance of the double-blind nature
of the trial. Urinary chloride and potassium were measured using ISE
indirect reagents for COBAS C, the measuring range for potassium is
3–100 mmol/L with an analytical variation of <5%, the measuring range
for chloride is 20–250 mmol/L, with an analytical variation of <5%.
Urinary glucose was measured using the GLUC3 pack for COBAS C,
the measuring range for urinary glucose is 0.11–249.6 mmol/L (normal
range: 0.06–0.83 mmol/L), with a variation of ∼1%. Urinary osmolal-
ity, the total number of solute particles (or osmoles) per kilogram of
fluid, was both measured and calculated in order to gain insight in
the constituents of urine osmolality. Urine osmolality was measured
using an automatic freezing point depression osmometer (Osmo Sta-
tion OM-6050, ARKRAY), with a measuring range of 0–2000 mOsm/kg
and an analytical variation of <1%. Between measurements tubes were
capped to prevent evaporation.
Aldosterone concentrations were measured using the Aldosterone
RIA kit by MT Diagnostics. Renin concentrations were measured using
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Table 2 Urinary parameters over the course of treatment
Empagliflozin (n = 40) Placebo (n = 39) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Spot urinary sodium (mmol/L)
Baseline 90± 31 87± 35 0.706
24 h 69± 28 85± 37 0.040
48 h 56± 29 79± 44 0.011
72 h 63± 41 70± 27 0.400
96 h 56± 29 69± 32 0.089
30 days 60± 30 56± 28 0.683
Fractional excretion of sodium (%)
Baseline 2.1 (0.9–4.1) 2.2 (0.9–4.4) 0.964
24 h 1.4 (0.9–2.4) 1.5 (0.6–3.2) 0.874
48 h 1.0 (0.3–1.7) 1.4 (0.7–2.1) 0.256
72 h 1.4 (0.8–1.7) 1.0 (0.6–2.3) 0.840
96 h 0.8 (0.4–1.9) 1.0 (0.7–1.7) 0.476
30 days 0.7 (0.3–1.7) 0.7 (0.4–2.0) 0.388
Spot urinary glucose (mmol/L)
Baseline 0.2 (0.1–0.3) 0.1 (0.1–0.2) 0.264
24 h 50.4 (17.1–94.8) 0.2 (0.1–0.3) <0.001
48 h 41.3 (17.2–79.1) 0.2 (0.1–0.3) <0.001
72 h 35.2 (16.2–96.2) 0.2 (0.1–0.3) <0.001
96 h 30.3 (9.9–75.2) 0.2 (0.1–0.4) <0.001
30 days 13.1 (1.6–58.9) 0.2 (0.1–0.3) <0.001
Fractional excretion of glucose (%)
Baseline 0.1 (0.1–0.1) 0.1 (0.0–0.1) 0.890
24 h 21.8 (10.1–29.8) 0.1 (0.1–0.1) <0.001
48 h 13.6 (5.4–24.0) 0.1 (0.0–0.1) <0.001
72 h 16.0 (4.2–24.4) 0.1 (0.0–0.1) <0.001
96 h 6.0 (2.5–21.8) 0.1 (0.0–0.1) <0.001
Spot urinary urea (mmol/L)
Baseline 108.0 (60.8–142.1) 97.5 (77.6–139.5) 0.881
24 h 136.0 (93.3–172.7) 124.0 (91.3–191.6) 0.935
48 h 160.2 (116.0–194.0) 159.3 (111.3–105.7) 0.840
72 h 154.5 (122.9–185.0) 157.5 (128.5–207.5) 0.426
96 h 179.6 (121.0–256.7) 172.2 (144.9–233.0) 0.427
30 days 214.0 (141.0–272.6) 166.6 (85.2–294.5) 0.333
Fractional excretion of urea (%)
Baseline 37.9 (30.3–45.0) 37.6 (28.0–48.5) 0.984
24 h 33.1 (28.6–41.9) 35.3 (21.4–43.0) 0.664
48 h 29.6 (22.2–39.3) 30.5 (25.7–39.7) 0.572
72 h 31.1 (26.3–37.1) 32.0 (24.9–39.2) 0.952
96 h 32.4 (24.2–38.0) 33.5 (29.5–39.0) 0.346
the Renin Kit III by Cis Bio International. Aldosterone and renin
measurements were performed in the Pharmacology Laboratory of the
Erasmus Medical Center Rotterdam.
Calculation of urinary osmolality was done according to the follow-
ing formula: osmolality = 2× [Na+]+ 2× [K+]+ [Glucose]+ [Urea],
with all concentrations being concentrations of molecules in urine.
The same formula was used to calculate plasma osmolality. All frac-
tional excretion percentages were calculated by a standard formula:
100%× FEx = (Ux × Pcreat)/(Px ×Ucreat), in which Ux is the urinary con-
centration of the analyte and Px represents the plasma concentration
of the analyte. Ucreat and Pcreat represent urinary and plasma concen-
trations of creatinine, respectively. In sensitivity analysis, estimated 24 h
urinary sodium excretion was calculated using the earlier defined for-
mula by the International Cooperative Study on Salt, Other Factors,





















Baseline characteristics were explored using a t-test for normally
distributed variables and a Mann–Whitney U test for non-normally
distributed variables. For further analysis, variables were normal-
ized by logarithmic transformation where necessary. The effect of
empagliflozin use on changes in clinical outcomes [i.e. estimated
glomerular filtration rate (eGFR); systolic blood pressure; plasma and
urinary osmolality; fractional excretion of sodium (FeNa), chloride
(FeCl) and glucose (FeGlu); renin; aldosterone] during 96 h and 30 days
were analysed with repeated measures linear mixed-effect (LME) mod-
els, which account for individual variations in changes and intercepts
by estimating the random effects per individual. To correct for their
highly skewed nature, renin and aldosterone were log-transformed
before being analysed in the linear mixed models. For each clinical
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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p= 0.494p= 0.714 p= 0.381 p= 0.618 p= 0.750








































































p= 0.954p= 0.568 p= 0.327 p= 0.654 p= 0.779
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Figure 1 Progression of fractional excretion of sodium (A), chloride (B) and glucose (C) over the course of treatment. For each clinical variable,
changes from baseline were calculated and used as outcomes in linear mixed-effect models. Two models were performed, one adjusted for
baseline values, the second model adjusted for baseline values and the interaction term between treatment and time. In each panel, the results
for the ANOVA tests between the two models is depicted (likelihood ratio and P-value). For placebo and empagliflozin, mean values are shown
with dots, the bars represent standard error. A P-value for interaction between each time point and treatment is shown.
variable, change from baseline was calculated and used as an outcome
in the LME model. We performed a nested model adjusted for base-
line values and time, whereas for each outcome a second model was
performed including baseline values, time, treatment arm and the treat-
ment x time interaction term. Further, we compared the two models
without and with the treatment interaction term using analysis of vari-
ance (ANOVA), where a P-value <0.05 was considered significant for
a treatment effect during the full treatment period (either 96 h or
30 days depending on the variable). The effects of empagliflozin on












.. for interaction terms P< 0.05. LME models were conducted using the
lme function in the ‘nlme’ package. All analyses were performed in R
studio, version 1.3.959.13
Results
Baseline characteristics of the study population have been pub-
lished elsewhere.9 In brief, patients were 76 (range 38–89)
years old, 33% were female and median N-terminal pro B-type
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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natriuretic peptide (NT-proBNP) was 5236 [interquartile range
(IQR) 3482–8276] pg/mL. Background medical treatment at
baseline was similar between the groups and there were no
differences in loop diuretic doses, vasodilator or inotrope use
or guideline-recommended HF medication. Baseline eGFR was
54±17 mL/min/1.73 m2, median plasma glucose was 7.8 (IQR
6.2–8.9) mmol/L and 33% had a history of type 2 diabetes mel-
litus. In urine, glucose concentrations at baseline were 0.1 (IQR
0.1–0.2) mmol/L, with low FeGlu [0.1 (IQR 0.1–0.1)%]. In urine,
baseline osmolality was 335 (IQR 322–380) mOsm/kg, whereas
median plasma osmolality was 305 (IQR 302–311) mOsm/kg.
Before start of randomized treatment but within 24 h of admission
and after initiation of loop diuretic therapy, spot urinary sodium
was 99 (IQR 67–111) mmol/L, with a FeNa of 2.2 (IQR 0.9–4.3)%.
No between group differences were observed between patients
treated with empagliflozin or placebo for any of these baseline
variables (Table 1).
Table 2 shows plasma and spot urinary electrolytes over time,
stratified by treatment arm. Empagliflozin significantly decreased
spot urinary sodium concentration as compared with placebo. The
most pronounced effect was seen after 48 h (56.2 vs. 79.0 mmol/L,
P = 0.011). In contrast, treatment with empagliflozin did not
change FeNa at any time point as compared with placebo (Table 2,
Figure 1A, P = 0.956 for ANOVA difference between models
with and without treatment interaction), indicating that while
net urinary sodium concentration decreases, a similar amount of
glomerularly filtered sodium is reabsorbed in the renal tubuli com-
pared with placebo. In sensitivity analysis, median calculated 24 h
sodium excretion after 24 h also did not show differences between
patients treated with empagliflozin compared with placebo
(P = 0.235). Moreover, no differences in the occurrence of hypona-
traemia were seen between both treatment arms (P> 0.2); delta
serum sodium from baseline to 96 h also did not change between
the treatment arms (−0.17 vs. −0.18 mmol/L, P = 0.99), nor did
empagliflozin change serum sodium at any time point (P = 0.302 for






















































.. interaction). Likewise, urinary chloride excretion was lower in
patients treated with empagliflozin, but FeCl was unaltered by
empagliflozin use (Figure 1B, P = 0.922 for ANOVA difference
between models with and without treatment interaction).
Empagliflozin significantly increased both urinary glucose con-
centration and FeGlu, with a peak in FeGlu after 24 h (median
21.8% vs. 0.1%, P< 0.001; Table 2, Figure 1C). Although FeGlu
decreased over the course of treatment, it was still significantly
higher in patients treated with empagliflozin compared with
placebo after 96 h (median 6.0% vs. 0.1%, P< 0.001). A similar
pattern was seen for urinary glucose concentration up to 30 days
of treatment (Table 2). Plasma glucose levels, however, were
not changed by empagliflozin use (P = 0.763 for ANOVA differ-
ence between models with and without treatment interaction).
FeGlu was similar in patients with and without diabetes in the
empagliflozin arm (P = 0.182 for interaction, online supplementary
Figure S2). Plasma urea was additionally increased in patients
treated with empagliflozin, while fractional excretion of urea and
urinary urea remained unaffected (P = 0.036, 0.99 and 0.782 for
ANOVA difference between models with and without treatment
respectively).
During the first 72 h, empagliflozin caused a significant decrease
in eGFR (−10± 12 vs. −2±12 mL/min/1.73 m2) compared with
placebo (P = 0.009), as shown in Table 3 and Figure 2A. This
significant decline in eGFR was attenuated at 96 h and 30 days
(P = 0.133 and 0.681 respectively). In addition, empagliflozin signif-
icantly increased urinary output (cumulative urinary output after
48 h: 6084± 2480 mL vs. 4222±1911 mL, P = 0.010; n = 41),
which resulted in a greater negative fluid balance [cumulative
fluid balance after 48 h: −3050 (IQR −1280 to −4753) mL vs.
−1200 mL (IQR −710 to −2425), P = 0.010; n = 38].
Although urinary volumes significantly increased after initia-
tion of empagliflozin, no impact on urinary osmolality was seen
(Figure 2C). In other words, the number of particles per kilogram
of urine did not change despite a larger urinary volume. How-
ever, a significant shift was seen in the constituents making up
Table 3 Estimated glomerular filtration rate over the course of treatment
Empagliflozin (n = 40) Placebo (n = 39) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
eGFR (mL/min/1.73 m2)
Baseline 53 ± 18 54 ±16 0.824
24 h 44 ± 14 52 ±19 0.022
48 h 43 ± 16 53 ±19 0.013
72 h 42 ± 16 54 ±18 0.006
96 h 45 ± 18 53 ± 20 0.101
30 days 50 ± 21 54 ±19 0.511
Change in eGFR from baseline (mL/min/1.73 m2)
24 h −9 ± 9 −2 ± 8 0.002
48 h −10 ±12 −2 ± 10 0.004
72 h −10 ±12 −2 ± 12 0.009
96 h −7 ±11 −3 ± 15 0.133
Day 30 −6 ±15 −4 ± 16 0.681
eGFR, estimated glomerular filtration rate.
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Study Group 1_Placebo 2_EmpagliflozinA
ANOVA difference without/with treatment interaction: L.Ratio=24, p−value <0.001




































































ANOVA difference without/with treatment interaction: L.Ratio=4, p−value 0.686



































































ANOVA difference without/with treatment interaction: L.Ratio=4, p−value 0.671
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Study Group 1_Placebo 2_EmpagliflozinD
ANOVA difference without/with treatment interaction: L.Ratio=9, p−value 0.1
8
Figure 2 Delta estimated glomerular filtration rate eGFR (A), delta systolic blood pressure progression (B), delta urine osmolality (C) and
delta plasma osmolality (D) over the course of treatment. For each clinical variable, changes from baseline were calculated and used as outcomes
in linear mixed-effect models. Two models were performed, one adjusted for baseline values, the second model adjusted for baseline values
and the interaction term between treatment and time. In each panel, the results for the ANOVA tests between the two models is depicted,
(likelihood ratio and P-value). For placebo and empagliflozin, mean values are shown with dots, the bars represent standard error. A P-value
for interaction between each time point and treatment is shown.
urine osmolality, with glucose making up a larger proportion of the
total urinary particles compared with placebo (Figure 3 and Graph-
ical Abstract). Measured and calculated urine osmolality showed
a strong correlation (r of log-transformed variables 0.91–0.99)
(online supplementary Table S1).
At baseline, plasma osmolality was similar in both groups. During
the first 72 h, empagliflozin modestly increased plasma osmolality











. P = 0.049). Moreover, we found a significant interaction for plasma
osmolality between time at 72 h and treatment effect (P = 0.031,
Figure 2D).
Median baseline renin was 28.8 (1.0–1820) pg/mL, median
baseline aldosterone was 185.9 (31.0–1810) pg/mL. Median
plasma renin concentration at baseline was higher in the placebo
group than in the empagliflozin group (12.4 pg/mL vs. 80.1 pg/mL,
P = 0.011). Empagliflozin significantly increased renin with a peak
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.





















































































Figure 3 Composites of urinary molecules making up osmolality. Osmolality per time point for both empagliflozin and placebo. Volumes
depicted on the bars represent total urinary volume per 24 h, y axis represents spot urinary osmolality. *n = 58; †n = 47; ‡n = 44; §n = 35.
after 72 h, after which a plateau was reached and significance was
lost (P = 0.016 for ANOVA between models with and without
treatment effect) (Figure 4A). Aldosterone was not altered by
empagliflozin use (P = 0.217 for ANOVA between models with
and without treatment effect) (Figure 4B).
No significant correlations, as analysed with linear regression,
could be seen for log FeGlu and log FeNa, for log FeGlu and fluid
balance or for log FeNa and fluid balance (online supplementary
Figure S1).
Discussion
In this pre-defined post-hoc analysis of the EMPA-RESPONSE-AHF





















. had a higher urinary output and a more negative fluid balance. Inter-
estingly, FeNa did not increase and urinary osmolality remained
similar between both groups. Nonetheless, FeGlu significantly
increased after initiation of empagliflozin. Moreover, empagliflozin
temporarily reduced renal function in the first days after an acute
HF hospital admission.
The increase in FeGlu with SGLT2 inhibition by empagliflozin was
expected, as blocking the receptor responsible for tubular reab-
sorption of glucose would intuitively lead to increased excretion of
filtered glucose. Importantly, FeGlu was similar in patients with and
without diabetes and plasma glucose levels remained unchanged,
suggesting that pre-existing diabetes and/or plasma glucose sup-
ply to the glomerulus do not play an important role. Our finding
that FeNa was not increased with empagliflozin was somewhat
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
8 E.M. Boorsma et al.
p= 0.988 p= 0.224 p= 0.396 p= 0.457 p= 0.171













































































Study Group Placebo EmpagliflozinB
p= 0.278 p= 0.001 p= 0.014 p= 0.095 p= 0.6780.0







































































Study Group Placebo EmpagliflozinA
Figure 4 Delta renin (A) and aldosterone (B) over the course of treatment. For renin and aldosterone (both log-transformed), changes from
baseline were calculated and used as outcomes in linear mixed-effect models. Two models were performed, one adjusted for baseline values,
the second model adjusted for baseline values and the interaction term between treatment and time. In each panel, the results for the ANOVA
tests between the two models is depicted (likelihood ratio and P-value). For placebo and empagliflozin, mean values are shown with dots, the
bars represent standard error. A P-value for interaction between each time point and treatment is shown.
unexpected, since blockage of the SGLT2 receptor in the prox-
imal tubule prevents reabsorption of both glucose and sodium.
However, it is well known that in contrast to glucose, sodium
can be reabsorbed throughout the entire tubule. Therefore, our
findings suggest that sodium reabsorption might have been blocked
by empagliflozin in the proximal tubule, and that this was compen-
sated by an increased reabsorption of sodium in the rest of the
tubule and collecting duct.14
Similar to a post-hoc analysis of the EMPA-REG OUTCOME
trial, a transient decline in eGFR was seen after initiating treatment
with empagliflozin.15 This course in eGFR over time was seen in the
CANVAS Program as well.16 This has been postulated to be related
to the juxtaglomerular feedback mechanism and a correction in
glomerular hyperfiltration.17,18 Loss of chloride is sensed by the
macula densa in the distal convoluted tubule and leads to release of
adenosine, causing afferent vasoconstriction and a decreased renal
blood flow, in order to spare salt. If we assume that the established
drop in glomerular filtration rate is indeed the result of activation
of the macula densa, there should still be high levels of sodium
and chloride present in the distal convoluted tubule in order
for juxtaglomerular feedback mechanism to be activated.19 This
would mean that although we do not find increased concentrations
of sodium in the urine, proximal tubular sodium resorption is
indeed diminished. This notion is further supported by the fact
that renin levels were increased compared with placebo for the
first 72 h, following a similar pattern compared to drop in eGFR.
The increased osmotic diuresis resulting from glycosuria probably









































. to be interpreted in light of background therapy and one should be
wary to draw conclusions based on these data alone. Consequently,
sodium is likely reabsorbed distally from the macula densa, e.g.
in the collecting duct. In the collecting ducts, multiple mediators
regulate urine dilution and sodium reabsorption, one of which is
vasopressin.20 Yet, since urinary osmolality remained unchanged
and vasopressin only plays a minor role in sodium reabsorption, it
is unlikely that an increase in vasopressin is truly responsible for
this increase in sodium reabsorption in the collecting duct. We did
not find an increase in aldosterone after initiation of empagliflozin,
making aldosterone an unlikely cause for distal tubular or collecting
duct sodium reabsorption. Other drivers of sodium reabsorption
include insulin and insulin-like growth factor-1, while endothelin-1
and nitric oxide decrease sodium reabsorption.21–23 The precise
contribution of each of these factors on sodium reabsorption in the
collecting duct after blocking the SGLT2 receptor and treatment
with loop diuretics should be assessed in future studies.
Interestingly, our data show a modest increase in plasma osmo-
lality. These effects were even more pronounced in patients with
lower serum sodium and lower plasma osmolality. In our data no
effect on serum sodium could be found, which might be explained
by the fact that only a small proportion of patients presented with
hyponatraemia and the lowest measured sodium upon admission
was 129 mmol/L. Moreover, this might position SGLT2 inhibitors
as a treatment for tissue congestion or residual congestion as
increased plasma osmolality attracts fluid from the interstitial space
into the blood stream.24 This notion is supported by earlier find-
ings that the SGLT2 inhibitor dapagliflozin has been calculated to
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reduce interstitial fluid volume three times more than it reduces
blood volume, compared to an interstitial fluid reduction of only
66% of the reduction in blood volume by bumetanide.25 The fact
that empagliflozin did not lower blood pressure in these severely
diseased patients despite larger negative fluid balance also sup-
ports the theory of a more stable refill rate from interstitial fluid
to plasma as a result of increased plasma osmolality (Figure 2B).
However, we should account for the small study group here and
the fact that other larger trials did find a reduction of 5–10 mmHg
in systolic blood pressure after initiation of a SGLT2 inhibitor.26,27
Still, this increase in plasma osmolality might also be expected since
distal diluting segments receive higher tubular flow as a result of
empagliflozin. The kidneys perceive this as a state of hypervolaemia
which, through stimulation of the countercurrent system of the
vasa recta, leads to more distal sodium reabsorption and less free
water clearance.28
As described earlier, the majority of HF patients are discharged
with residual congestion with consequent impaired prognosis.29
Our analyses might provide insights into new possibilities to
overcome residual congestion due to significantly improved net
fluid loss (negative fluid balance) and increased plasma osmolality.
Naturally, our data need to be validated in other (larger) clinical
cohorts.
Taken together, our findings that empagliflozin increased FeGlu,
while both FeNa and urinary osmolality remained unchanged, sug-
gest that empagliflozin most prominently stimulates osmotic diure-
sis as a result of increased FeGlu instead of natriuresis. Our results
are in line with earlier studies that reported that SGLT2 inhibitors
increased urinary volume without an increase in FeNa.8,30 In
another study comprising of patients with type 2 diabetes and sta-
ble chronic HF (median NT-proBNP: 399 pg/mL), an early increase
in urinary sodium excretion was seen. However, in this study fluid
administration was high in these patients, sodium intake was not
standardized per protocol, and intermittent urinary measurements
were only obtained throughout the first 6 h. Therefore, the cir-
cadian rhythm in sodium excretion could still have affected these
findings. Since we included acute HF patients with more signs and
symptoms of fluid congestion (median NT-proBNP: 5236 pg/mL),
differences might further be explained by our sicker cohort with
likely even higher neurohumoral activation potentially leading to
increased sodium reabsorption and eventually maintaining FeNa
constant. This is in contrast to a study in patients with euvolaemic,
stable HF, where empagliflozin increased both FeGlu and FeNa, and
even exhibited a small synergistic effect of concomitant treatment
with intravenous bumetanide.7
Limitations
Several potential limitations of the present study can be identified.
The first limitation of this study is the relatively small sample size.
Second, we collected spot urine samples and not 24 h measure-
ments. Consequently, we do not know the total sodium output
over the course of hospitalization. Conceivably, increased volumes
of urine, even with a lower concentration of sodium, will eventually
lead to an increased absolute total of urinary sodium. As per pro-



















































































.. urinary excretion of glucose. However, urinary levels of sodium
excretion were measured in the local labs and could therefore be
perceived in the electronic medical records. Third, plasma levels of
glucose were not measured at the 30-day follow-up visit, as this was
not incorporated in the study protocol. Therefore, no FeGlu could
be calculated at day 30. Fourth, the timing of loop diuretic admin-
istration was not standardized. This was left to the discretion of
the treating physician. Therefore, some patients were on continu-
ous loop diuretic infusion, while others were on intravenous bolus
loop diuretic treatment. So, the natriuretic effect of a recent loop
diuretic bolus, rather than that of empagliflozin cannot be ruled out.
Still, considering the randomized nature of this trial, these treat-
ment differences should be equal in both arms. Moreover, patients
in both treatment arms were on equal total doses of intravenous
and oral loop diuretics, and the number of patients on either oral or
intravenous loop (bolus vs. continuous) diuretics was similar as well
(online supplementary Table S2). Additionally, calculating fractional
excretion levels relies on measured plasma creatinine levels. These
values changed throughout follow-up, which might have affected
calculated values of fractional excretion.
Conclusion
In patients hospitalized with acute HF, empagliflozin caused an
increase in urinary output, FeGlu and plasma osmolality, with-
out affecting FeNa or urine osmolality. Additionally, a significant,
temporary decline in eGFR was seen. These results suggest that
empagliflozin primarily stimulates osmotic diuresis in patients with
acute HF through increased glycosuria rather than through natri-
uresis.
Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
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